In conclusion, this study is consistent with the hypothesis that inhibition of IL‐6 signalling does not directly affect renal function, supporting this approach as a therapeutic opportunity for reducing the risk of CVD in patients with CKD. This evidence concerns the gene IL6 and chronic kidney disease.